Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Thursday

Maravai LifeSciences (NASDAQ:MRVI) is expected to be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $57.79 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Maravai LifeSciences Stock Performance

Shares of MRVI opened at $4.08 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences has a one year low of $4.04 and a one year high of $11.56. The firm has a market capitalization of $1.03 billion, a P/E ratio of -2.49 and a beta of -0.08. The business has a fifty day moving average of $5.13 and a 200 day moving average of $6.73.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MRVI shares. Wolfe Research started coverage on Maravai LifeSciences in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada reduced their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their target price for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Robert W. Baird cut their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Finally, William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Maravai LifeSciences currently has an average rating of “Hold” and a consensus price target of $10.28.

Insiders Place Their Bets

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares in the company, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.63% of the stock is currently owned by company insiders.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.